Eugia Pharma Receives USFDA Approval for Sodium Nitroprusside Injection, 50 mg/2 mL Single-Dose Vials
Published: December 10, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sodium Nitroprusside Injection, 50 mg/2 mL Single-Dose Vials.
Indications for this product include:
- Immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises;
- Producing controlled hypotension in order to reduce bleeding during surgery;
- Treatment of acute congestive heart failure.
Refer to package insert for full prescribing information including Boxed Warning.